DLA Piper advised the underwriters for Scynexis, Inc., a drug discovery and development company, in its US$63 million initial public offering. RBC Capital Markets and Canaccord Genuity are acting as joint book-running managers. JMP Securities is participating as lead manager in the offering.

The DLA Piper team representing the underwriters was led by partner Curtis L. Mo (Silicon Valley and San Francisco), corporate associates Torrie Nute, Alina Azizian and Christopher Trester (Silicon Valley), life sciences regulatory lawyer Rebecca McKnight (Austin), and intellectual property counsel Stacy Taylor (San Diego).

This marks the fourth IPO in the United States handled by DLA Piper this year. Since 2008, the firm’s Capital Markets group has represented companies, underwriters and placement agents in approximately 240 public offerings (equity and debt) in the US and worldwide, including more than 40 IPOs.